Chromosomal damage induced by caprolactam in human lymphocytes.
Caprolactam was tested in the in vitro human lymphocyte cytogenetic assay both in the presence and absence of S9 mix at dose levels up to 5500 micrograms/ml using lymphocytes obtained from a male donor and in the presence of S9 mix using lymphocytes obtained from a female donor. Statistically significant increases in chromosomal damage were observed at 5500 micrograms/ml dose level in cells from both donors. This positive response was enhanced by the inclusion of chromosomal gaps in the calculations. It was concluded that caprolactam induces chromosomal damage in human lymphocytes in vitro albeit at comparatively high dose levels.
Sheldon
T
T
Imperial Chemical Industries plc, Central Toxicology Laboratory, Macclesfield, Ches., Great Britain.
D001381:Azepines / Q000633:toxicity*; D001711:Biotransformation; D002209:Caprolactam / Q000493:pharmacokinetics / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D009153:Mutagens / Q000493:pharmacokinetics
D001381:Azepines; D009153:Mutagens; D002209:Caprolactam